Raw data for efficacy and safety from: Intra-articular sodium hyaluronate for ankle-involved Kashin-Beck disease: A 12-month prospective self-controlled study

This dataset contains raw data from a 12-month prospective self-controlled
study evaluating intra-articular sodium hyaluronate for ankle-involved
Kashin-Beck disease (KBD). The dataset is presented as a structured CSV
file with data from 79 adult patients diagnosed with ankle-involved KBD.
All enrolled patients received three consecutive weekly intra-articular
sodium hyaluronate injections (2 mL/vial, 20 mg) in the affected ankle.
The data includes: 1) Basic patient information (e.g., KBD stage, no
personal identifiers to protect privacy); 2) outcome measures assessed at
three time points: baseline (before the first injection), Week 4 (one week
after the third injection), and Month 12 (12 months after the first
injection); and 3) specific outcome variables: Graded Chronic Pain Scale
(GCPS) scores for pain intensity, KBD Joint Dysfunction Index (JDI) scores
for joint function, and EQ-5D-3L utility index for quality of life. All
numerical values are original source data that have only undergone
standard calculation/conversion per validated scales (no post-statistical
processing). GCPS pain scores range from 0 to 100, JDI scores from 0 to
10, and the EQ-5D-3L utility index from 0.170 to 1.000. The
"null" represents "data not collected as preset in the
study protocol," rather than "missing or omitted data," and
is explained in the accompanying README file, ensuring no ambiguity for
data users. This dataset is valuable for: 1) Secondary analysis of sodium
hyaluronate efficacy in ankle-involved KBD (e.g., subgroup analysis by KBD
stage, long-term effect verification); 2) Methodological research on
prospective self-controlled study designs in musculoskeletal diseases; and
3) Comparative studies with other KBD treatment datasets (e.g., comparing
efficacy of different conservative treatments).